LQDA - Liquidia Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$74.83
DETAILS
HIGH:
$109.00
LOW:
$60.00
MEDIAN:
$71.50
CONSENSUS:
$74.83
DOWNSIDE:
0.58%
About Liquidia Corporation (https://www.liquidia.com)
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Roger A. Jeffs | Chief Executive Officer & Director | 1962 | $2,121,744 USD |
| Michael Kaseta | Chief Operating Officer & Chief Financial Officer | 1976 | $1,406,072 USD |
| Russell Schundler | General Counsel & Corporate Secretary | 1976 | $1,171,097 USD |
| Rajeev Saggar | Chief Medical Officer | 1975 | $1,166,848 USD |
| Scott Moomaw | Chief Commercial Officer | 1971 | $980,961 USD |
| Christian Perez Font | Senior Vice President, Chief Compliance Officer & Associate General Counsel | – | – |
| Dana Boyle | Chief Accounting Officer | 1985 | – |
| Matt Snow | Senior Vice President of Sales | – | – |
| Michael Post | Senior Vice President of Marketing | – | – |
| Sarah Krepp SPHR | Chief Human Resources Officer | 1982 | – |